Stephen McCarthy
Medical · Bethlehem, PANPI 1912308743
Payments from drug & device makers
Across 311 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$828
- Alkermes, Inc.$682
- Johnson & Johnson$681
- AbbVie$553
- Vanda Pharmaceuticals Inc.$478
- plus $1K from 10 others
What the payments were for
- Food & beverage$6,10598%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 86 | $1,849 |
| Otsuka America Pharmaceutical, Inc. | 39 | $828 |
| Alkermes, Inc. | 26 | $682 |
| Johnson & Johnson | 30 | $681 |
| AbbVie(2 entities) | 28 | $553 |
| Vanda Pharmaceuticals Inc. | 31 | $478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $290 |
| Supernus Pharmaceuticals, Inc. | 10 | $264 |
| Neos Therapeutics, LP | 14 | $181 |
| Ironshore Pharmaceuticals Inc. | 9 | $124 |
| Sunovion Pharmaceuticals Inc. | 5 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Orexo US, Inc. | 3 | $47 |
| Lundbeck LLC | 2 | $40 |
| Braeburn Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$499
- LYBALVI$499
- INVEGA SUSTENNA$259
- ARISTADA INITIO$125
- QELBREE$125
- REXULTI$125
- Austedo XR$125
- UBRELVY$122
How this compares
$6,228 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 14 | $32,146 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $25,124 |
| Clozapine | 39 | $3,919 |
| Risperidone | 64 | $2,925 |
| Divalproex Sodium | 61 | $2,824 |
| Olanzapine | 38 | $1,916 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $1,468 |
| Aripiprazole | 21 | $1,411 |
| Quetiapine Fumarate | 46 | $1,196 |
| Hydroxyzine Hcl | 42 | $1,075 |
| Carbamazepine ErCarbamazepine | 13 | $981 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $949 |
| Trazodone Hcl | 24 | $803 |
| Fluoxetine Hcl | 37 | $737 |
| Topiramate | 19 | $705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $478 | $32,14614 claims |
| Alkermes, Inc.Lybalvi | $682 | $25,12415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Bethlehem
- Meghan HoffnerBethlehem$86K
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.